Legal Investigations Launched into Leggett & Platt, Pulmatrix, and Assertio Acquisitions Over Pricing Fairness

Legal scrutiny over M&A activity has expanded as Kahn Swick & Foti, LLC launched an investigation into the proposed sale of Assertio Holdings to Garda Therapeutics for $18.00 per share plus a contingent value right (CVR). Simultaneously, the firm has joined existing probes by Ademi LLP and Halper Sadeh LLC into the acquisition of Leggett & Platt by Somnigroup International, where shareholders are set to receive 0.1455 shares for each share held. The merger between Pulmatrix and Eos SENOLYTIX also remains under investigation, with concerns regarding the 6% stake retained by Pulmatrix stockholders. These probes focus on whether boards of directors failed to maximize shareholder value or conduct a transparent sale process. Such litigation often introduces short-term uncertainty and potential delays in closing transactions. Investors are monitoring these developments closely as they could impact the final terms of the merger agreements.